Document is current
Any future updates will be listed below
-
Authors
Cultrara, Christopher
Uhl, Christopher
Kirby, Kenneth
Abed Elrazaq, Essam
Zellander, Amelia
Andrews, David W
Scott, Charles B
Galluzzi, Lorenzo
Exley, Mark A
Zilberberg, Jenny https://orcid.org/0000-0002-4139-2616
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02507583 at ClinicalTrials.govnct04485949 at ClinicalTrials.govDocuments that mention this clinical trial
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma
https://doi.org/10.1136/jitc-2023-006880
410 Goldspire<sup>TM</sup>: a biologic-device combination platform engineered to induce anti-tumor responses against solid tumors via immunogenic cell death (ICD)
https://doi.org/10.1136/jitc-2024-sitc2024.0410
1071 Autologous tumor cell immunotherapeutic platform induces stress-correlated immunogenic cell death leading to immune activation within the draining lymph nodes
https://doi.org/10.1136/jitc-2022-sitc2022.1071
nct02507583 at ClinicalTrials.govDocuments that mention this clinical trial
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma
https://doi.org/10.1136/jitc-2023-006880
410 Goldspire<sup>TM</sup>: a biologic-device combination platform engineered to induce anti-tumor responses against solid tumors via immunogenic cell death (ICD)
https://doi.org/10.1136/jitc-2024-sitc2024.0410
nct02507583 at ClinicalTrials.govDocuments that mention this clinical trial
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma
https://doi.org/10.1136/jitc-2023-006880
410 Goldspire<sup>TM</sup>: a biologic-device combination platform engineered to induce anti-tumor responses against solid tumors via immunogenic cell death (ICD)
https://doi.org/10.1136/jitc-2024-sitc2024.0410
1071 Autologous tumor cell immunotherapeutic platform induces stress-correlated immunogenic cell death leading to immune activation within the draining lymph nodes
https://doi.org/10.1136/jitc-2022-sitc2022.1071
Documents that mention this clinical trial
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma
https://doi.org/10.1136/jitc-2023-006880
410 Goldspire<sup>TM</sup>: a biologic-device combination platform engineered to induce anti-tumor responses against solid tumors via immunogenic cell death (ICD)
https://doi.org/10.1136/jitc-2024-sitc2024.0410
1071 Autologous tumor cell immunotherapeutic platform induces stress-correlated immunogenic cell death leading to immune activation within the draining lymph nodes
https://doi.org/10.1136/jitc-2022-sitc2022.1071
- License Information
